Plant-Derived Cannabis Formula Granted ‘Breakthrough’ Designation by FDA for Pain Treatment

Regulators at the US Food and Drug Administration have granted ‘Breakthrough Therapy Designation’ to a proprietary cannabis extract (VER-01) containing 2.5 milligrams of THC and standardized percentages of CBD and CBG (cannabigerol). A press release issued by the product’s manufacturer, VERTANICAL, states that the designation “is intended to expedite the development and review of investigational medicines where preliminary clinical evidence indicates the potential for substantial improvement over available therapies.” The FDA’s decision follows the results…